Heart failure clinical care analysis uncovers risk reduction opportunities for preserved ejection fraction subtype
Abstract Heart failure (HF) has no cure and, for HF with preserved ejection fraction (HFpEF), no life-extending treatments. Defining the clinical epidemiology of HF could facilitate earlier identification of high-risk individuals. We define the clinical epidemiology of HF subtypes (HFpEF and HF with...
Guardado en:
Autores principales: | Rebecca T. Levinson, Nataraja Sarma Vaitinidin, Eric Farber-Eger, Dan M. Roden, Thomas A. Lasko, Quinn S. Wells, Jonathan D. Mosley |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/16365d18d17547e3b97bbedbf892776a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Suppression of Tumourigenicity 2 in Heart Failure With Preserved Ejection Fraction
por: Veronika Zach, et al.
Publicado: (2020) -
Effects of Exercise Training on Cardiac Function in Heart Failure with Preserved Ejection Fraction
por: Hidekatsu Fukuta
Publicado: (2020) -
Delayed repolarization and ventricular tachycardia in patients with heart failure and preserved ejection fraction.
por: Jae Hyung Cho, et al.
Publicado: (2021) -
A profile of heart failure with preserved ejection fraction in a teaching institute
por: Gaurav Aggarwal, et al.
Publicado: (2021) -
Transcriptomic Research in Heart Failure with Preserved Ejection Fraction: Current State and Future Perspectives
por: Sebastian Rosch, et al.
Publicado: (2020)